Letters, Testimony & Comments

March 3, 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and Chemical Weapons Research Act as introduced by Senator Joseph Lieberman. (Mar. 3, 2002).
February 26, 2002
The biotechnology industry is the most research and development intensive and capital-focused industry in the world. As such, it is very dependent on a robust intellectual property system as well as a strong set of competition laws. Recent...
February 5, 2002
Testimony of Dr. Una S. Ryan President and CEO, AVANT Immunotherapeutics, Inc. Before the Subcommittee on Science, Technology, and Space Senate Committee on Commerce, Science, and Transportation Tuesday, February 5, 2002   Mr....
January 8, 2002
FDA's Pediatric Rule Early Rule. In 1994 FDA issued a regulation requiring manufacturers of marketed drugs to survey existing data and to determine whether the data were sufficient to support additional pediatric use information in the...
December 13, 2001
For the second time this year, BIO along with PhRMA filed a petition for a write of certiorari before the Supreme Court. The petition filed on Thursday Eli Lilly and Company v. Barr Laboratories Inc., asks the Supreme Court to address and correct...
December 10, 2001
On December 10th, 2001, the Supreme Court held that Utility patents may be issued for plants under 35 U.S.C. 101 despite distinct protections available under the Plant Variety Protection Act and the Plant Patent Act. Affirming the Federal Circuit...
December 7, 2001
Good morning. My name is Michael Werner. I am Vice President for Bioethics for the Biotechnology Industry Organization (BIO). BIO represents more than 1,000 biotechnology companies and academic institutions in all 50 states. More than 90 percent...
November 15, 2001
Regarding funding for the U.S. Patent and Trademark Office
October 29, 2001
By Carl B. Feldbaum At a time when national security is understandably monopolizing Congress's legislative calendar, as well as the energies of the federal agencies that regulate biotechnology, I am pleased to report that the biotechnology...
October 23, 2001
TESTIMONY OF STEPHEN G. SUDOVAR President and CEO EluSys Therapeutics, Inc. 10 Bloomfield Ave. Pine Brook, NJ 07058 973-808-0222 (phone) 973-808-0322 (fax) Committee on Government Reform Subcommittee on National Security, Veterans Affairs...
October 23, 2001
TESTIMONY U.S. House of Representatives Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and International Relations Hearing on Biological Warfare Defense Vaccine Research & Development Programs 10:00 A...
October 1, 2001
Outling BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusity bill.
October 1, 2001
Outlining BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusivity bill
September 26, 2001
The Honorable Michael Harris, M.P.P. Premier of Ontario Legislative Assembly of Ontario Room 281 Legislative Building Toronto, Ontario M7A 1A1 Dear Premier Harris: I read with concern your remarks about modifying Canadian patent laws to...
July 26, 2001
Honorable Michael Bilirakis Chairman Subcommittee on Health Committee on Energy and Commerce U.S. House of Representatives 2125 Rayburn Building Washington, DC 20015 Dear Mr. Chairman: On June 13, your Subcommittee held a hearing...
July 13, 2001
Dan Eramian, Vice President Communications Biotechnology Industry Organization Athersys Cleveland, Ohio July 13, 2001 Let me start by telling you a little about the Biotechnology Industry Organization, or BIO. We are the national...
July 11, 2001
Written Statement of J. Craig Venter, PhD, President, Celera Genomics On Behalf of The Biotechnology Industry Organization (BIO) Before the Subcommittee on Consumer Protection US House Committee on Energy and Commerce July 11, 2001 Good...
June 20, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products for...